title: [Platinum compounds in cancer therapy--past, present, and future].
abstract: Platinum cytotoxics play an important role globally in the management of solid tumours. Cisplatin sets the standard for efficacy in both regions with careful administration to reduce nephrotoxicity. Carboplatin is associated with neurotoxicity, but has become the leading product in the US due largely to the easier to manage toxicity profile. Both agents have been widely used in both registered and non registered indications and are frequently combined with other cytotoxics. In Japan, cisplatin has been used successfully at low doses in combination with 5-FU based regimens and appears to achieve a synergistic effect, but controlled data are not yet available. More recently oxaliplatin (Europe) and nedaplatin (in Japan) have been introduced, but their clinical roles in therapy have yet to be established. One of the limiting features of the first generation of platinum compounds is that a significant proportion of tumours develop cross resistance to platins due to either changes in uptake or excretion, intracellular detoxification or accelerated DNA repair. The forum discussed the possibility for the development of better new platinum compounds, A new platin agent which had lower toxicity and higher efficacy across a wide range of cancers without the development of resistance would be a significant step forward. If the tolerability profile was suitable, an oral formulation may improve the quality of life for patients but this must not be at the expense of efficacy. Even after the introduction of new target based drugs, platinum cytotoxics are likely to be used to reduce the tumour mass and in some cases can be expected to potentiate the effects of the new agents. In preclinical studies, ZD0473 has been shown to by-pass some major mechanisms of resistance and has the potential to achieve these objectives and is now being evaluated in clinical studies in both Japan and the West.
authors.affiliation: Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba.
authors.forename: H
authors.initials: H
authors.lastname: Akaza
authors.forename: N
authors.initials: N
authors.lastname: Saijo
authors.forename: K
authors.initials: K
authors.lastname: Aiba
authors.forename: S
authors.initials: S
authors.lastname: Isonishi
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
authors.forename: K
authors.initials: K
authors.lastname: Kawai
authors.forename: T
authors.initials: T
authors.lastname: Konishi
authors.forename: T
authors.initials: T
authors.lastname: Saeki
authors.forename: S
authors.initials: S
authors.lastname: Sone
authors.forename: S
authors.initials: S
authors.lastname: Tsukagoshi
authors.forename: T
authors.initials: T
authors.lastname: Tsuruo
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: T
authors.initials: T
authors.lastname: Miki
authors.forename: O
authors.initials: O
authors.lastname: Mikami
authors.forename: M
authors.initials: M
authors.lastname: Smith
authors.forename: G
authors.initials: G
authors.lastname: Hoctin-Boes
authors.forename: D
authors.initials: D
authors.lastname: Stribling
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D005544:Forecasting; D006801:Humans; D000077146:Irinotecan; D008495:Medical Oncology / Q000639:trends; D009369:Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D000077150:Oxaliplatin; D010984:Platinum / Q000627:therapeutic use*
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D010984:Platinum; D000077146:Irinotecan; D016190:Carboplatin; D002945:Cisplatin; D002166:Camptothecin